tiprankstipranks
Phathom Pharmaceuticals (PHAT)
NASDAQ:PHAT
US Market

Phathom Pharmaceuticals (PHAT) Ownership - Who Owns Phathom Pharmaceuticals?

247 Followers

Phathom Pharmaceuticals (PHAT) Ownership Overview

40.23%8.06%20.99%30.72%
40.23% Insiders
20.99% Other Institutional Investors
30.72% Public Companies and
Individual Investors
The ownership structure of Phathom Pharmaceuticals (PHAT) stock is a mix of institutional, retail and individual investors. Approximately 29.05% of the company’s stock is owned by Institutional Investors, 40.23% is owned by Insiders and 30.72% is owned by Public Companies and Individual Investors.
The ownership structure of Phathom Pharmaceuticals (PHAT) stock is a mix of institutional, retail and individual investors. Approximately 29.05% of the company’s stock is owned by Institutional Investors, 40.23% is owned by Insiders and 30.72% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Apr 10, 2024
Molly Henderson
Cfo And Cbo
xxxxxxxxxxxxx
$38129
Jan 25, 2024
xxxxxxxxxxxxx
$29999994
Nov 21, 2023
Molly Henderson
Cfo And Cbo
xxxxxxxxxxxxx
$15399
Nov 08, 2023
Asit Parikh
Director
xxxxxxxxxxxxx
$58580

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024
xxxxxxxxxxxxx
$205815
Mar 31, 2024
xxxxxxxxxxxxx
$1274400
Mar 31, 2024
xxxxxxxxxxxxx
$6015582
Mar 31, 2024
xxxxxxxxxxxxx
$10807092

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
2,095,429Institution3.58%22,934,470
1,764,927Institution3.02%19,317,126
1,635,039Institution2.79%17,895,502
1,017,617Institution1.74%11,137,818
566,439Institution0.97%6,199,675
521,935Institution0.89%5,712,579
464,839Institution0.79%5,087,663
417,422Institution0.71%4,568,684
355,173Institution0.61%3,887,368
342,203Institution0.58%3,745,412

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
1,635,039Institution2.79%17,895,502
464,839Institution0.79%5,087,663
417,422Institution0.71%4,568,684
355,173Institution0.61%3,887,368
342,203Institution0.58%3,745,412
249,398Institution0.43%2,729,661
229,213Institution0.39%2,508,736
161,865Institution0.28%1,771,612
160,000Institution0.27%1,751,200
159,626Institution0.27%1,747,107

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,297,116Institution2.22%13,360,295
901,681Institution1.54%9,868,899
521,935Institution0.89%5,712,579
548,307Institution0.94%5,647,562
248,743Institution0.42%2,722,492
208,294Institution0.36%2,279,778
162,923Institution0.28%1,821,479
127,037Institution0.22%1,308,481
96,441Institution0.16%993,342
79,900Institution0.14%874,506

FAQ

Who Owns Phathom Pharmaceuticals (PHAT)?
According to the latest TipRanks data, approximately 20.99% of the company's stock is held by institutional investors, 40.23% is held by insiders, and 30.72% is held by retail investors.
    What percentage of Phathom Pharmaceuticals (PHAT) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 20.99% of Phathom Pharmaceuticals (PHAT) stock is held by institutional investors.
      What percentage of Phathom Pharmaceuticals (PHAT) stock is held by retail investors?
      According to the latest TipRanks data, approximately 30.72% of Phathom Pharmaceuticals (PHAT) stock is held by retail investors.
        Who owns the most shares of Phathom Pharmaceuticals (PHAT)?
        Vanguard owns the most shares of Phathom Pharmaceuticals (PHAT).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis